Мобильный 1 Add news
March 2010
April 2010
May 2010June 2010July 2010
August 2010
September 2010October 2010
November 2010
December 2010
January 2011
February 2011March 2011April 2011May 2011June 2011July 2011August 2011September 2011October 2011November 2011December 2011January 2012February 2012March 2012April 2012May 2012June 2012July 2012August 2012September 2012October 2012November 2012December 2012January 2013February 2013March 2013April 2013May 2013June 2013July 2013August 2013September 2013October 2013November 2013December 2013January 2014February 2014March 2014April 2014May 2014June 2014July 2014August 2014September 2014October 2014November 2014December 2014January 2015February 2015March 2015April 2015May 2015June 2015July 2015August 2015September 2015October 2015November 2015December 2015January 2016February 2016March 2016April 2016May 2016June 2016July 2016August 2016September 2016October 2016November 2016December 2016January 2017February 2017March 2017April 2017May 2017June 2017July 2017August 2017September 2017October 2017November 2017December 2017January 2018February 2018March 2018April 2018May 2018June 2018July 2018August 2018September 2018October 2018November 2018December 2018January 2019February 2019March 2019April 2019May 2019June 2019July 2019August 2019September 2019October 2019November 2019December 2019January 2020February 2020March 2020April 2020May 2020June 2020July 2020August 2020September 2020October 2020November 2020December 2020January 2021February 2021March 2021April 2021May 2021June 2021July 2021August 2021September 2021
News Every Day |

Moderna’s COVID-19 Vaccine Still 93% Effective After 6 Months, Company Says



Moderna said its COVID-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.

A final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The 93% effectiveness level is just short of the shot’s initial efficacy of 94%.

Concern that the effectiveness of COVID-19 vaccines could wane has stoked talk of booster shots, and some countries have begun to offer vulnerable people third doses. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated. The recommendation could limit the reach of Moderna’s shot, called Spikevax.
[time-brightcove not-tgx=”true”]

The shares fell 2.9% as of 8:28 a.m. before U.S. markets opened Thursday. COVID-19 vaccine-maker Pfizer lost 0.6%, while its partner BioNTech shed 3.8%.

Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released. Despite the apparent endurance of its vaccine, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.

All three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.

Seeking Approval

Cambridge, Massachusetts-based Moderna also said it expected to complete its submission for full Food and Drug Administration approval for its vaccine this month.

The agency is already reviewing the submission for a rival messenger RNA vaccine from Pfizer Inc. and BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.

Moderna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its COVID-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.

The company said in the release it has signed $20 billion worth of COVID-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion COVID vaccine doses this year.

Seeking Deals

Moderna’s views for total sales of its COVID-19 vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.

Moderna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&P 500 last month and is the index’s best performer this calendar year.

As the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a presentation.

Moderna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson & Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.

Read also

Aliyu Ibrahim-Gaya emerges new Emir of Gaya

North Korea and South Korea in a possible inter-Korean summit: Japan on sidelines

The ten regions with the most job vacancies revealed and which industries are hiring

Слот 7

News, articles, comments, with a minute-by-minute update, now on Today24.pro

News Every Day

Collagen Peptides Market Projected to Deliver Greater Revenues By 2027

Today24.pro — latest news 24/7. You can add your news instantly now — here


Блоги

Рейтинг проектов с самыми высокими потолками в премиальном сегменте




Новости России
Game News

Авторы Marvel's Avengers помогут перезапустить Perfect Dark


Russian.city


Елена Веснина

Воры вернули Весниной олимпийскую золотую медаль и оставили подарок с запиской


Губернаторы России
#123ru.net

Шоу «Битва экстрасенсов» вернётся в эфир с новым сезоном и новым скептиком


Путин назвал примером для молодежи отмечающую юбилей школу «Самбо-70»

Артур Бетербиев: «Советская школа бокса уже не чисто советская. Все смешивается»

Столичные парки подготовили новую познавательную онлайн-программу

Кемеровчане сравнили новый терминал аэропорта «Алексей Леонов» с АвтоВАЗом


Экс-солистка «Ленинграда» Алиса Вокс проиграла суд Сергею Шнурову

Суд отклонил иск бывшей солистки «Ленинграда» Алисы Вокс к Сергею Шнурову

Анна Нетребко пересказала легенду о Коромысловой башне Нижегородского кремля

Певец Николай Попов получил "Орден России"


Победитель US Open Медведев может не сыграть на Кубке Кремля

СМИ: грабители вернули украденные у теннисистки Весниной медали с коробкой конфет

Смотреть онлайн Петер Годжовчик — Карен Хачанов. ATP Мец. Теннис. Прямая трансляция 23 сентября 2021

Прямая трансляция матчей квалификации турнира WTA Astana Open с участием казахстанских теннисисток




Навальный обжаловал запрет Google выдавать фразу "Умное голосование"

Лукашенко прибыл в Сочи с частным визитом

Вирусолог Нетесов заявил, что в России нет четвертой волны коронавируса

«Батя» в Каннах: комедийный сериал стал единственным российским проектом в конкурсе Canneseries в категории шорт-форм


Победа или поражение? Почему принципиальные коммунисты недовольны верхушкой КПРФ

Свердловская область лидирует в антирейтинге по числу случаев загрязнения рек

В России и Москве продолжается поствыборный рост новых случаев ковида

Появилось видео с места нападения водителя иномарки на сотрудников ДПС в Москве



Путин в России и мире







Персональные новости
Moscow.media